Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy

Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy

Brentuximab vedotin, an antibody drug conjugate that delivers monomethyl auristatin E into CD-30 expressing cells is FDA approved for the treatment of patients with Hodgkin lymphoma after the failure of autologous stem cell transplantation or at least 2 prior multi-agent chemotherapy regiments. This...

Full description

Bibliographic Details
Main Authors: Wilbur Montana, Dennis Andrew Buck, Tristan Smith
Format: Article
Language:English
Published: Karger Publishers 2017-09-01
Series:Case Reports in Oncology
Subjects:
Brentuximab
Concurrent radiation
Classical Hodgkin lymphoma
Online Access:http://www.karger.com/Article/FullText/479224

Internet

http://www.karger.com/Article/FullText/479224

Similar Items